Chief Financial Officer
Mike is an experienced financial executive with close to 20 years of CFO tenure in public and private companies in the biotech, med tech and consulting industries. Mike has significant experience in raising capital, building high performance teams, and developing and implementing strategies to support late-stage clinical trials and first-time commercial launches. Most recently Mike was CFO of Karyopharm Therapeutics, where he helped the company and the finance team prepare for the commercialisation of its first product XPOVIO for treatment of multiple myeloma. Prior to Karyopharm, Mike served as CFO for Seven Bridges Genomics, Analysis Group, Ahura Scientific, and Aspect Medical Systems.
Mike began his biotech career as VP of Finance at Millennium Pharmaceuticals, where his team provided the financial strategy and support for the launch of Velcade for treatment of multiple myeloma. Earlier in his career, Mike served in financial management positions with Fidelity Investments, Digital Equipment Corporation and General Electric. Mike earned a BS in Foreign Service from Georgetown University and an MS in Management from the Sloan School at MIT.